$COR

DURCAN DERMOT MARK purchased $1.1M of COR

DURCAN DERMOT MARK purchased 4,000 shares of Cencora, Inc. (COR) at $266.26 ($1.07M total) on 2026-05-28.

Original reporting
SEC EDGAR · DURCAN DERMOT MARK
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$COR
Bullish
medium confidence
Mentioned
$COR
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 4,000 shares at a stated price, which can marginally support sentiment but does not provide new guidance, earnings, or deal information.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but it is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not explain motivation, and insider buying alone rarely changes valuation without accompanying operational catalysts.

Relevance 7/10Novelty 4/10Timing: Filed 2026-05-28, after-hours/close timing for the same trading day.

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora, Inc. (COR).

Company-level read

Ticker impact

$CORBullishMedium confidence
Context

Cencora Form 4 shows director Durcan Dermot Mark bought 4,000 shares at $266.26 on 2026-05-28, totaling $1.07M.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by broader disclosures.

Evidence & confidence

The filing is a primary-source insider transaction with clear size and price, but it does not include new company performance, strategy, or regulatory developments.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine, tax-related, or driven by personal liquidity needs, so they may not reflect a new fundamental outlook.

Key entities

  • Cencora, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • DURCAN DERMOT MARK

    Director who reported the open-market purchase.

Related articles

$CORMed

The Bull Case For Cencora (COR) Could Change Following Raised EPS Outlook And Bigger Buybacks And Dividend

Cencora (COR) reported Q3 2026 sales of $84.75B and net income of $763.5M, and amended credit and receivables facilities, expanding revolving capacity to $7.0B. The company raised its fiscal 2026 adjusted EPS outlook, completed a $2.0B buyback tranche, and declared a $0.60 quarterly dividend. It flagged a possible earnings headwind tied to an MWI Animal Health-Covetrus merger.

$CORMedAI 8/10

Cencora Q3 Earnings Call Highlights

Cencora (NYSE:COR) reported Q3 results on its earnings call. U.S. Healthcare Solutions operating income rose 16% to $966 million, and International revenue grew 6% to $7.7 billion with operating income up 21% to $166 million. The company expects fiscal 2026 consolidated adjusted operating income growth of 13% to 14%, and said OneOncology integration is modestly ahead of initial expectations.

$CORMed

Cencora, Inc. Q3 2026 Earnings Call Summary

Cencora reported Q3 2026 results driven by specialty pharmaceutical strength in health systems and physician practices, with its MSO platforms (including OneOncology and RCA) ahead of expectations. Adjusted EPS guidance for fiscal 2026 was raised to $17.75 to $17.95. The company completed $1 billion of share repurchases, expects U.S. Healthcare Solutions revenue in the lower half of 4% to 6% growth, and cited a $0.35 EPS headwind from the pending MWI Animal Health merger.

$CORHigh

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q32026.htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48 Adjusted